A discount recognizes a customer category. It does not show that a substance is permitted for a service member, compatible with duties or appropriate for human use. These questions remain separate even when a seller uses military imagery or describes its products as research materials.

Use the relevant official resource

Operation Supplement Safety is the Department of Defense's dietary supplement and substance education program. Its prohibited-ingredient resource is a starting point for checking current policy information. The exact ingredient identity matters, and a brand name or abbreviated product name may not be enough to perform a reliable check. Department of Defense Operation Supplement Safety DoD prohibited dietary supplement ingredient list

A dietary-supplement list is also not a universal classification system for every drug or laboratory reagent. An item absent from one list should not automatically be treated as cleared for use. Service-specific requirements, medical documentation and the actual intended use can require additional professional guidance.

Separate purchase terms from evidence

A percentage discount provides no information about batch identity, clinical evidence, manufacturing quality or product authorization. The FTC's health-claim guidance applies to the underlying claims rather than the emotional appeal of a promotion. An endorsement or testimonial cannot supply missing scientific support. FTC Health Products Compliance Guidance

For a legitimate laboratory purchase, the institution's procurement and research controls still apply. For treatment, the appropriate route is clinical assessment and an authorized source. A research-only label should not be used as a bridge between those activities.

AXON has not verified a military discount, eligibility program or service-member approval for any product in this article. If AXON later introduces a commercial program, its terms would need separate verification and should not imply military endorsement. The educational priority is to help readers distinguish a marketing incentive from an official substance-policy decision and a medical decision.